YUHSpace

BROWSE

Export
87 147

Cited 0 times in

Cited 0 times in

Correspondence to editorial on "Sorafenib vs. Lenva-tinib in advanced hepatocellular carcinoma after at-ezolizumab/bevacizumab failure: A real-world study"

DC Field Value Language
dc.contributor.authorChon, Young Eun-
dc.contributor.authorKim, Dong Yun-
dc.contributor.authorChon, Hong Jae-
dc.contributor.authorKim, Do Young-
dc.date.accessioned2025-02-03T09:15:01Z-
dc.date.available2025-02-03T09:15:01Z-
dc.date.created2025-06-30-
dc.date.issued2024-10-
dc.identifier.issn2287-2728-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/202325-
dc.description.abstract[No abstract available]-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherKorean Association for the Study of the Liver-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleCorrespondence to editorial on "Sorafenib vs. Lenva-tinib in advanced hepatocellular carcinoma after at-ezolizumab/bevacizumab failure: A real-world study"-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorChon, Young Eun-
dc.contributor.googleauthorKim, Dong Yun-
dc.contributor.googleauthorChon, Hong Jae-
dc.contributor.googleauthorKim, Do Young-
dc.identifier.doi10.3350/cmh.2024.0394-
dc.relation.journalcodeJ00557-
dc.identifier.eissn2287-285X-
dc.identifier.pmid38816178-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordImmune check point inhibitor-
dc.subject.keywordAtezolizumab and bevacizumab failure-
dc.subject.keywordSalvage therapy-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthorKim, Dong Yun-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.identifier.scopusid2-s2.0-85208616733-
dc.identifier.wosid001359201700006-
dc.citation.volume30-
dc.citation.number4-
dc.citation.startPage1005-
dc.citation.endPage1008-
dc.identifier.bibliographicCitationCLINICAL AND MOLECULAR HEPATOLOGY, Vol.30(4) : 1005-1008, 2024-10-
dc.identifier.rimsid87201-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorHepatocellular carcinoma-
dc.subject.keywordAuthorImmune check point inhibitor-
dc.subject.keywordAuthorAtezolizumab and bevacizumab failure-
dc.subject.keywordAuthorSalvage therapy-
dc.subject.keywordPlusOPEN-LABEL-
dc.subject.keywordPlusPLUS-
dc.type.docTypeLetter-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.description.journalRegisteredClasskci-
dc.relation.journalWebOfScienceCategoryGastroenterology & Hepatology-
dc.relation.journalResearchAreaGastroenterology & Hepatology-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Show simple item record Find it @ YMLIB

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links